Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push
NEW YORK, April 1 —
Eli Lilly agreed to acquire Centessa Pharmaceuticals plc (CNTA) for up to $7.8bn, paying $6.3bn upfront to get the biotech's orexin receptor pipeline.
- Total deal value: up to $7.8bn, with $6.3bn in upfront cash and the remainder in contingent value rights
- CNTA shares hit an all-time high post-announcement but still trade at a ~38% discount to the full deal price
- Two hurdles remain: regulatory and antitrust clearance, plus CVR milestone triggers that unlock the remaining $1.5bn
Why It Matters
The deal hands Lilly a pipeline of sleep-wake disorder treatments — a category with growing patient demand and few competitors. Centessa's orexin receptor agonists fill a hole Lilly couldn't build on its own in any reasonable timeframe. Lilly put $6.3bn on the table upfront, a large bet from a company that has been picky about neuroscience acquisitions.
For CNTA shareholders, the deal reprices a company with just $15mn in trailing twelve-month revenue at a massive premium. The stock's negative forward P/E of -24.2x tells you this is a pre-revenue biotech — Lilly is buying clinical-stage assets, not earnings. Options volume has spiked as traders bet on the spread between the current share price of $39.72 and the implied deal value.
The ~38% gap between CNTA's trading price and the full $7.8bn consideration is wider than typical pharma takeouts. That spread reflects two separate risks: whether regulators approve the deal, and whether Centessa's drugs hit the CVR milestones that trigger the remaining $1.5bn. Buyers at this price are betting on both.
The Risk
An antitrust challenge or adverse regulatory ruling could delay or kill the deal, wiping out the merger premium. The $1.5bn in CVRs hinges on specific clinical and commercial milestones. If Centessa's pipeline data disappoints after close, Lilly shareholders eat the loss — but CNTA holders who sold at market never collect the full payout. A competing bid is unlikely given Lilly's scale, but one would reset the math entirely.
Centessa Pharmaceuticals does not yet have a dedicated research page on Basis Report — visit the CNTA stock page to generate a full analysis including pipeline valuation and deal-spread tracking.
Basis Report does not hold positions in securities discussed. This is not investment advice.